(3S,5R)-fluvastatin sodium : An organic sodium salt resulting from the replacement of the proton from the carboxy group of (3S,5R)-fluvastatin by a sodium ion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 23679527 |
| CHEMBL ID | 241778 |
| CHEBI ID | 77603 |
| CHEBI ID | 5137 |
| SCHEMBL ID | 41663 |
| SCHEMBL ID | 41503 |
| MeSH ID | M0026775 |
| Synonym |
|---|
| smr000705060 |
| MLS002154037 |
| fluvastatin sanabo |
| 6-heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3,5-dihydroxy-, monosodium salt, (r*,s*-(e))-(+-)- |
| fractal |
| fluindostatin |
| fluvastatin sodium [usan] |
| primesin |
| locol |
| lipaxan |
| lymetel |
| sodium (+-)-(3r*,5s*,6e)-7-(3-(p-fluorophenyl)-1-isopropylindol-2-yl)-3,5-dihydroxy-6-heptenoate |
| ccris 6848 |
| lescol xl |
| lescol (tn) |
| fluvastatin sodium (jan/usp) |
| D00892 |
| HMS2097L19 |
| HMS3067L20 |
| unii-pyf7o1fv7f |
| pyf7o1fv7f , |
| fluvastatin sodium [usan:usp] |
| dtxsid3044758 , |
| CHEMBL241778 |
| F0820 |
| 94061-81-1 |
| (3s,5r)-fluvastatin sodium salt |
| (3s,5r)-7-(3-(4-fluorophenyl)-1-isopropyl-1h-indol-2-yl)-3,5-dihydroxyhept-6-enoic acidsodium salt |
| sodium, (e)-(3s,5r)-7-[3-(4-fluoro-phenyl)-1-isopropyl-1h-indol-2-yl]-3,5-dihydroxy-hept-6-enoate |
| (-)-3s,5r-fluvastatin sodium salt |
| almastatin |
| AKOS015894901 |
| (3s,5r) fluvastatin sodium salt |
| primexin |
| 6-heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3,5-dihydroxy-, monosodium salt, (r*,s*-(e))-(+/-)- |
| fluvastatin sodium [usp monograph] |
| fluvastatin sodium [jan] |
| fluvastatin sodium [usp-rs] |
| fluvastatin sodium [ep monograph] |
| sodium (+/-)-(3r*,5s*,6e)-7-(3-(p-fluorophenyl)-1-isopropylindol-2-yl)-3,5-dihydroxy-6-heptenoate |
| fluvastatin sodium [who-dd] |
| fluvastatin sodium [usp impurity] |
| fluvastatin sodium [vandf] |
| fluvastatin sodium [orange book] |
| fluvastatin sodium salt [mi] |
| fluvastatin sodium [mart.] |
| CCG-220859 |
| SCHEMBL41663 |
| SCHEMBL41503 |
| sodium (3s,5r,6e)-7-[3-(4-fluorophenyl)-1-isopropyl-1h-indol-2-yl]-3,5-dihydroxyhept-6-enoate |
| (3s,5r)-fluvastatin sodium |
| (-)-(3s,5r)-fluvastatin sodium |
| (-)-fluvastatin sodium |
| CHEBI:77603 , |
| (3s,5r)-(-)-fluvastatin sodium |
| sodium (3s,5r,e)-7-(3-(4-fluorophenyl)-1-isopropyl-1h-indol-2-yl)-3,5-dihydroxyhept-6-enoate |
| (3s,5r)-rel-7-[3-(4-fluorophenyl)-1-isopropyl-1h-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid sodium salt |
| mfcd00929076 |
| fluvastatin sodium, united states pharmacopeia (usp) reference standard |
| fluvastatin for system suitability, european pharmacopoeia (ep) reference standard |
| fluvastatin sodium, pharmaceutical secondary standard; certified reference material |
| fluvastatin sodium, european pharmacopoeia (ep) reference standard |
| J-009181 |
| HMS3714L19 |
| rel-(3s,5r,e)-7-(3-(4-fluorophenyl)-1-isopropyl-1h-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid, sodium salt |
| Q27147205 |
| HY-14664C |
| (3s,5r)-fluvastatin (sodium) |
| CS-0019898 |
| sodium;(e,3s,5r)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoate |
| 6-heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl]-3,5-dihydroxy-, sodium salt , (3s,5r,6e)- |
| A917249 |
| rel-sodium (3s,5r,e)-7-(3-(4-fluorophenyl)-1-isopropyl-1h-indol-2-yl)-3,5-dihydroxyhept-6-enoate |
| (3r,5s,6e)-(+/-)-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3,5-dihydroxy-6-heptenoic acid |
| fluvastatin sodium (mart.) |
| rac-sodium (3r,5s,6e)-7-(3-(4-fluorophenyl)-1-isopropyl-1h-indol-2-yl)-3,5-dihydroxyhept-6-enoate |
| fluvastatin sodium (usp impurity) |
| sodium (+-)-(3r,5s,6e)-7-(3-(4-fluorophenyl)-1-isopropyl-1h-indol-2-yl)-3,5-dihydroxyhept-6-enoate |
| (+-)-sodium (3r,5s,6e)-7-(3-(4-fluorophenyl)-1-isopropyl-1h-indol-2-yl)-3,5-dihydroxyhept-6-enoate |
| fluvastatin sodium (usp monograph) |
| (3rs,5sr,6e)-sodium-7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3,5-dihydroxy-6-heptenoate |
| (+-)-fluvastatin sodium |
| fluvastatin sodiumer |
| chebi:5137 |
| lescolxl |
| fluvastatin sodium (ep monograph) |
| fluvastatin sodium (usp-rs) |
| Class | Description |
|---|---|
| organic sodium salt | |
| statin (synthetic) | A statin which does not occur naturally and which is not obtained by chemical transformation of a naturally occurring statin. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 19.9526 | 0.0447 | 17.8581 | 100.0000 | AID485341 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 0.0757 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 3.1623 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| TDP1 protein | Homo sapiens (human) | Potency | 23.7246 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| P53 | Homo sapiens (human) | Potency | 25.1189 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
| IDH1 | Homo sapiens (human) | Potency | 8.1995 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 5.8048 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 28.1838 | 0.6561 | 9.4520 | 25.1189 | AID463254 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 63.0957 | 1.1998 | 14.6419 | 50.1187 | AID488837 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 1.4125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 1.4125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 1.4125 | 0.1585 | 5.2879 | 12.5893 | AID540303 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 2.8184 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 3.1623 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 14.1254 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 37.9330 | 0.0601 | 10.7453 | 37.9330 | AID485367 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| photoreceptor-specific nuclear receptor | Homo sapiens (human) | IC50 (µMol) | 0.9510 | 0.0374 | 2.9340 | 8.9620 | AID624394 |
| transactivating tegument protein VP16 [Human herpesvirus 1] | Human alphaherpesvirus 1 (Herpes simplex virus type 1) | IC50 (µMol) | 2.2400 | 0.9460 | 4.7016 | 9.4870 | AID624395 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (117.93) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||